Table 1.
Renal adverse events in various CAR T-cell trials.
| Trial name | Indication | Kidney adverse events |
|---|---|---|
| KARMMA 3 (15) | Multiple myeloma | 3% (versus 2% on SOC) |
| KARMMA 1 (10) | Multiple myeloma | No relevant findings (no SAE) |
| CARTITUDE 1 (11) | Multiple myeloma | No relevant findings (no SAE) |
| CARTITUDE 4 (8) | Multiple myeloma | 1% (versus 1.4% SOC) |
| JULIET (16) | Non-Hodgkin lymphoma | Increased blood creatinine level (any grade) 11%, SAE 4% (no SAE) |
| ZUMA 1 (17) | Non-Hodgkin lymphoma | No relevant findings (no SAE) |
| ZUMA 7 (18) | Non-Hodgkin lymphoma | Acute kidney injury 2% all + 1% SAE versus SOC 5% all + 2% SAE |
| BELINDA (19) | Non-Hodgkin lymphoma | Creatinine increase 17.9% all + 1.2% SAE versus SOC 18.1% all + 0.6% SAE |
SOC, standard of care; SAE, serious adverse events.